立体定向放射治疗在枕骨大孔脑膜瘤中的作用。

IF 3.9 2区 医学 Q1 CLINICAL NEUROLOGY
Zhishuo Wei, Ajay Niranjan, Mishika Mehta, Suchet Taori, Khushi Rai, Hansen Deng, Constantinos G Hadjipanayis, L Dade Lunsford
{"title":"立体定向放射治疗在枕骨大孔脑膜瘤中的作用。","authors":"Zhishuo Wei, Ajay Niranjan, Mishika Mehta, Suchet Taori, Khushi Rai, Hansen Deng, Constantinos G Hadjipanayis, L Dade Lunsford","doi":"10.1227/neu.0000000000003625","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Management options for foramen magnum meningiomas (FMM) include observation, attempts at surgical resection, and radiation therapy. The authors report the single-institution long-term experience of the use of primary or adjuvant stereotactic radiosurgery (SRS) for FMMs.</p><p><strong>Methods: </strong>A total of 40 FMM patients (29 female) underwent SRS between 1987 and 2022. The median age at SRS was 62.0 (range: 30-82) years. Ten patients had prior surgical resection (2 gross total resections, 8 subtotal resections), whereas 4 patients had prior fractionated radiation therapy. Tumors were located at the anterior midline (5 patients), anterior lateral (25 patients), posterior midline (5 patients), and posterior lateral (5 patients) quadrants. The median prescription dose was 12.5 Gy (range: 10-16), and the median cumulative FMM tumor volume treated was 2.3 cc (range: 0.35-12.0).</p><p><strong>Results: </strong>The median follow-up time was 88.0 months (range: 12-253). Fourteen patients had a follow-up >5 years, and 12 additional patients had >10-year follow-ups. Complete imaging response was noted in 1 patient, partial regression was noted in 13 patients, and 25 patients had no further growth. One patient had tumor progression 9 months after initial SRS and then underwent repeat surgical resection. The overall local tumor control rate was 98%. A total of 35 patients had improved or stable neurological symptoms after SRS, and 5 patients reported delayed worsening of symptoms. Ten patients were deceased at the last clinical follow-up. The median overall survival was 102 months (range: 41-164). None of the patients died related to central nervous system disease progression. No post-SRS adverse radiation effects were detected.</p><p><strong>Conclusion: </strong>Progressive FMM presents a management challenge. In this experience, SRS effectively prevented local tumor progression and preserved neurological function. Our experience supports the role of SRS as a primary or adjuvant management strategy.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role of Stereotactic Radiosurgery in Patients With Foramen Magnum Meningiomas.\",\"authors\":\"Zhishuo Wei, Ajay Niranjan, Mishika Mehta, Suchet Taori, Khushi Rai, Hansen Deng, Constantinos G Hadjipanayis, L Dade Lunsford\",\"doi\":\"10.1227/neu.0000000000003625\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Management options for foramen magnum meningiomas (FMM) include observation, attempts at surgical resection, and radiation therapy. The authors report the single-institution long-term experience of the use of primary or adjuvant stereotactic radiosurgery (SRS) for FMMs.</p><p><strong>Methods: </strong>A total of 40 FMM patients (29 female) underwent SRS between 1987 and 2022. The median age at SRS was 62.0 (range: 30-82) years. Ten patients had prior surgical resection (2 gross total resections, 8 subtotal resections), whereas 4 patients had prior fractionated radiation therapy. Tumors were located at the anterior midline (5 patients), anterior lateral (25 patients), posterior midline (5 patients), and posterior lateral (5 patients) quadrants. The median prescription dose was 12.5 Gy (range: 10-16), and the median cumulative FMM tumor volume treated was 2.3 cc (range: 0.35-12.0).</p><p><strong>Results: </strong>The median follow-up time was 88.0 months (range: 12-253). Fourteen patients had a follow-up >5 years, and 12 additional patients had >10-year follow-ups. Complete imaging response was noted in 1 patient, partial regression was noted in 13 patients, and 25 patients had no further growth. One patient had tumor progression 9 months after initial SRS and then underwent repeat surgical resection. The overall local tumor control rate was 98%. A total of 35 patients had improved or stable neurological symptoms after SRS, and 5 patients reported delayed worsening of symptoms. Ten patients were deceased at the last clinical follow-up. The median overall survival was 102 months (range: 41-164). None of the patients died related to central nervous system disease progression. No post-SRS adverse radiation effects were detected.</p><p><strong>Conclusion: </strong>Progressive FMM presents a management challenge. In this experience, SRS effectively prevented local tumor progression and preserved neurological function. Our experience supports the role of SRS as a primary or adjuvant management strategy.</p>\",\"PeriodicalId\":19276,\"journal\":{\"name\":\"Neurosurgery\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1227/neu.0000000000003625\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003625","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:枕骨大孔脑膜瘤(FMM)的治疗选择包括观察、手术切除和放射治疗。作者报告了单一机构使用初级或辅助立体定向放射手术(SRS)治疗fmm的长期经验。方法:1987年至2022年间,共40例FMM患者(女性29例)接受了SRS。SRS的中位年龄为62.0岁(范围:30-82岁)。10例患者既往行手术切除(2例全切除,8例次全切除),4例既往行分次放疗。肿瘤位于前中线(5例)、前外侧(25例)、后中线(5例)和后外侧(5例)象限。中位处方剂量为12.5 Gy(范围:10-16),治疗的中位累积FMM肿瘤体积为2.3 cc(范围:0.35-12.0)。结果:中位随访时间为88.0个月(范围:12-253)。14例患者随访5年,另外12例患者随访10年。1例患者出现完全影像学反应,13例患者出现部分消退,25例患者无进一步生长。1例患者在首次SRS后9个月肿瘤进展,然后再次手术切除。局部肿瘤总体控制率为98%。共有35例患者在SRS后神经系统症状改善或稳定,5例患者报告症状延迟恶化。最后一次临床随访时,10例患者死亡。中位总生存期为102个月(范围:41-164)。没有患者因中枢神经系统疾病进展而死亡。没有检测到srs后的不良辐射效应。结论:进行性FMM对管理提出了挑战。在这个经验中,SRS有效地阻止了局部肿瘤的进展并保留了神经功能。我们的经验支持SRS作为主要或辅助治疗策略的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Role of Stereotactic Radiosurgery in Patients With Foramen Magnum Meningiomas.

Background and objectives: Management options for foramen magnum meningiomas (FMM) include observation, attempts at surgical resection, and radiation therapy. The authors report the single-institution long-term experience of the use of primary or adjuvant stereotactic radiosurgery (SRS) for FMMs.

Methods: A total of 40 FMM patients (29 female) underwent SRS between 1987 and 2022. The median age at SRS was 62.0 (range: 30-82) years. Ten patients had prior surgical resection (2 gross total resections, 8 subtotal resections), whereas 4 patients had prior fractionated radiation therapy. Tumors were located at the anterior midline (5 patients), anterior lateral (25 patients), posterior midline (5 patients), and posterior lateral (5 patients) quadrants. The median prescription dose was 12.5 Gy (range: 10-16), and the median cumulative FMM tumor volume treated was 2.3 cc (range: 0.35-12.0).

Results: The median follow-up time was 88.0 months (range: 12-253). Fourteen patients had a follow-up >5 years, and 12 additional patients had >10-year follow-ups. Complete imaging response was noted in 1 patient, partial regression was noted in 13 patients, and 25 patients had no further growth. One patient had tumor progression 9 months after initial SRS and then underwent repeat surgical resection. The overall local tumor control rate was 98%. A total of 35 patients had improved or stable neurological symptoms after SRS, and 5 patients reported delayed worsening of symptoms. Ten patients were deceased at the last clinical follow-up. The median overall survival was 102 months (range: 41-164). None of the patients died related to central nervous system disease progression. No post-SRS adverse radiation effects were detected.

Conclusion: Progressive FMM presents a management challenge. In this experience, SRS effectively prevented local tumor progression and preserved neurological function. Our experience supports the role of SRS as a primary or adjuvant management strategy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurosurgery
Neurosurgery 医学-临床神经学
CiteScore
8.20
自引率
6.20%
发文量
898
审稿时长
2-4 weeks
期刊介绍: Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery. Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信